Neoantigen DNA vaccine
Sponsors
Washington University School of Medicine
Conditions
Extensive-stage Small Cell Lung CancerMetastatic Hormone-Sensitive Prostate CancerRenal Cell CarcinomaSolid Tumor, AdultTNBC - Triple-Negative Breast CancerTriple Negative Breast CancerTriple Negative Breast NeoplasmsTriple-negative Breast Carcinoma
Phase 1
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
TerminatedNCT03199040
Start: 2019-07-23End: 2023-05-01Updated: 2024-05-28
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
CompletedNCT03532217
Start: 2018-09-14End: 2022-07-25Updated: 2022-08-05
Phase 2
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
WithdrawnNCT03598816
Start: 2020-08-31End: 2024-05-31Updated: 2020-08-13
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Active, not recruitingNCT04397003
Start: 2022-03-30End: 2029-09-30Updated: 2025-10-22